Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK NanoKTN counts 3,000th member, courts stronger bioscience interest

This article was originally published in Clinica

Executive Summary

The UK’s Nanotechnology Knowledge Transfer Network (NanoKTN) is celebrating its 3,000th member. The government-backed initiative, which was established to support the exploitation and commercialisation of micro and nanotechnology (MNT) generally, is designed to provide a forum linking the MNT R&D sector with the wider industry through collaborations between suppliers and users. Its Healthcare & Life Sciences group boasts 270 members, and the network is seeking to attract further interest in the bioscience and other sectors of this industry, a spokesperson told Clinica. Earlier this year, the NanoKTN unveiled plans to set up a medtech-specific Nanotechnology in Medical Devices (NiMeD) focus group (www.clinica.co.uk, 1 March 2012).

You may also be interested in...



US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.

CMS Removes Some Stark Law ‘Bureaucratic Barriers’ In Final Rule

The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

Topics

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel